Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 14, 2015, 35 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $78.54 to $2,171,047.50.

Highlighted Stocks Traded by Insiders:

Vical (VICL) - FREE Research Report

Samant Vijay B, who is President & CEO at Vical, sold 4,737 shares at $1.12 on Jan. 14, 2015. Following this transaction, the President & CEO owned 910,776 shares meaning that the stake was reduced by 0.52% with the 4,737-share transaction.

Bilinsky Igor, who is Sr VP, Corporate Development at Vical, sold 1,335 shares at $1.16 on Jan. 14, 2015. Following this transaction, the Sr VP, Corporate Development owned 126,313 shares meaning that the stake was reduced by 1.05% with the 1,335-share transaction.

Smith Lawrence Russell, who is VP, Vaccine Research at Vical, sold 1,912 shares at $1.16 on Jan. 14, 2015. Following this transaction, the VP, Vaccine Research owned 174,977 shares meaning that the stake was reduced by 1.08% with the 1,912-share transaction.

The shares most recently traded at $1.13, down $0.03, or 2.27% since the insider transaction. Historical insider transactions for Vical go as follows:

  • 4-Week # shares bought: 564,494
  • 4-Week # shares sold: 428
  • 12-Week # shares bought: 564,494
  • 12-Week # shares sold: 428
  • 24-Week # shares bought: 564,494
  • 24-Week # shares sold: 45,913

The average volume for Vical has been 411,100 shares per day over the past 30 days. Vical has a market cap of $97.6 million and is part of the health care sector and drugs industry. Shares are up 11.43% year-to-date as of the close of trading on Wednesday.

Vical Incorporated is engaged in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Currently, there is 1 analyst who rates Vical a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on VICL - FREE

TheStreet Quant Ratings rates Vical as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Vical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Tiptree Financial (TIPT) - FREE Research Report

Barnes Michael Gene, who is Executive Chairman at Tiptree Financial, bought 10,958 shares at $7.65 on Jan. 14, 2015. Following this transaction, the Executive Chairman owned 1.1 million shares meaning that the stake was boosted by 1.04% with the 10,958-share transaction.

The average volume for Tiptree Financial has been 21,300 shares per day over the past 30 days. Tiptree Financial has a market cap of $245.4 million and is part of the financial sector and insurance industry. Shares are down 6.3% year-to-date as of the close of trading on Wednesday.

TipTree Financial Inc., formerly Care Investment Trust, operates as a real estate investment trust (REIT). It engages in originating and acquiring healthcare-related real estate and commercial mortgage debt.

Exclusive Offer: Get the latest Stock Analysis on TIPT - FREE

TheStreet Quant Ratings rates Tiptree Financial as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, generally high debt management risk and weak operating cash flow. Get the full Tiptree Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hospira (HSP) - FREE Research Report

Stober Matthew R, who is SVP, Operations at Hospira, sold 2,000 shares at $61.80 on Jan. 14, 2015. Following this transaction, the SVP, Operations owned 50,967 shares meaning that the stake was reduced by 3.78% with the 2,000-share transaction.

The shares most recently traded at $61.60, down $0.20, or 0.32% since the insider transaction. Historical insider transactions for Hospira go as follows:

  • 4-Week # shares sold: 7,547
  • 12-Week # shares sold: 7,547
  • 24-Week # shares sold: 7,547

The average volume for Hospira has been 998,200 shares per day over the past 30 days. Hospira has a market cap of $10.4 billion and is part of the health care sector and drugs industry. Shares are up 0.9% year-to-date as of the close of trading on Wednesday.

Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. The company has a P/E ratio of 31.7. Currently, there is 1 analyst who rates Hospira a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HSP - FREE

TheStreet Quant Ratings rates Hospira as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Hospira Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null